Stocksigma LogoStocksigma Logo

Aurobindo Pharma Subsidiary Unit-II Concludes US FDA Inspection with One Procedural Observation

The US FDA concluded an inspection of Unit-II, an API manufacturing facility of Apitoria Pharma Private Limited鈥攁 wholly owned subsidiary of Aurobindo

Aurobindo Pharma Subsidiary Unit-II Concludes US FDA Inspection with One Procedural Observation

Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 15 Sept 2026, 11:44 pm

Aurobindo Pharma Subsidiary Unit-II Concludes US FDA Inspection with One Procedural Observation The US FDA concluded an inspection of Unit-II, an API manufacturing facility of Apitoria Pharma Private Limited鈥攁 wholly owned subsidiary of Aurobindo Pharma鈥攍ocated at Kazipally Industrial Area, Telangana, conducted between 7th Sep'26 and 15th Sep'26. The inspection closed with one procedural observation. The company stated it will submit a response to the US FDA within the stipulated timeline while maintaining robust quality and compliance standards across its manufacturing operations.

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements